Drugs News and Research

RSS

ERC funds DiaDrug project to study the link between insulin resistance and albuminuria

The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007. In total, 2503 proposals were submitted to the second Starting Grant call.

11 Sep 2009

Biomarker Discovery Service from Arrayit to unravel mystery of genetic links for human disease states

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service.

11 Sep 2009

Quintiles partners with the University of Pretoria

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines.

11 Sep 2009

Drug manufacturers are seeking out needle-free systems

Many of the novel biopharmaceutical drugs developed now can only be delivered by injection, and this has biologic manufacturers seeking out the most patient-friendly options, including needle-free systems.

11 Sep 2009

Neurologists recommend oral cladribine for treating multiple sclerosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.

11 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

GENova Biotherapeutics to obtain three new drug target patents

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

11 Sep 2009

Biomarkers for rapid identification of treatment effectiveness in major depression

Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.

11 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

Adamis Pharmaceuticals' Epinephrine injection categorized as a generic

Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company’s Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) (“PFS”). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company’s PFS in their generic category.

11 Sep 2009

Medicare reimbursement cuts will affect cancer care system

The Community Oncology Alliance (COA), a national non-profit organization that represents oncologists and other cancer care providers, strongly opposes cuts in Medicare reimbursement for cancer care outlined by the Centers for Medicare & Medicaid Services (CMS).

11 Sep 2009

eChIP genetic technique developed to examine FA proteins with DNA crosslinks

While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.

11 Sep 2009

Children's Hospital to determine optimal duration of antimicrobial treatment for UTIs

In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

11 Sep 2009

No change in students' drinking habits: Study

U.S. colleges with the biggest student drinking problems have so far failed to turn the tide, according to a new study.

11 Sep 2009

Study in Asia finds monkey malaria strain more widespread in humans than previously thought

"Researchers in Malaysia have confirmed that a form of malaria thought to primarily affect monkeys can infect and kill humans, according to a study published in Clinical Infectious Diseases journal," Agence France-Presse reports.

11 Sep 2009

Better use of quality-of-care ratings can lead to greater consumer control

A hospital pneumonia survival rate of 93 percent may sound good, but knowing that it's actually merely "fair" can help people pick a better hospital, according to new research. A "good" survival rate would be from 95 percent to 98 percent, medical experts say.

11 Sep 2009

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009.

10 Sep 2009

TrKA and CCM2 combination results in pediatric tumour regression

Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer. Further research towards a better understanding of the mechanism of action might hopefully lead, in the future, to the development of drugs that will be able to induce regression of certain tumors.

10 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009